Skip to main content
Erschienen in: Clinical and Experimental Nephrology 4/2018

01.08.2018 | Original article

Glucosuria and all-cause mortality among general screening participants

verfasst von: Kunitoshi Iseki, Tsuneo Konta, Koichi Asahi, Kunihiro Yamagata, Shouichi Fujimoto, Kazuhiko Tsuruya, Ichiei Narita, Masato Kasahara, Yugo Shibagaki, Toshiki Moriyama, Masahide Kondo, Chiho Iseki, Tsuyoshi Watanabe, For the “Design of the Comprehensive Health Care System for Chronic Kidney Disease (CKD) Based on the Individual Risk Assessment by Specific Health Check”

Erschienen in: Clinical and Experimental Nephrology | Ausgabe 4/2018

Einloggen, um Zugang zu erhalten

Abstract

Background

Dipstick urine tests are used for general health screening in Japan, but how the test results (e.g., glucosuria) relate to mortality is unknown.

Methods

Subjects participated in a nationwide screening in 2008 in six districts in Japan. We identified those who might have died using the national database of death certificates from 2008 to 2012 (total registered ~ 6 million) and verified candidates with the regional National Health Insurance Agency and public health nurses. Diabetes mellitus (DM) was defined as HbA1c ≥ 6.5%, fasting blood glucose ≥ 126 mg/dl, or medicated for DM. Hazard ratio (HR) and 95% confidence interval (CI) were calculated by Cox proportional hazard analysis. Glucosuria was defined as dipstick ≥ 1 +.

Results

Among 209,060 subjects, we identified 2714 fatalities (median follow-up 3.57 years). Crude mortality rates were 1.2% for those without glucosuria and 3.4% for those with glucosuria. After adjusting for sex, age, body mass index, comorbidity (DM, hypertension, and dyslipidemia), history (stroke, heart disease, and kidney disease), and lifestyle (smoking, drinking, walking, and exercise), the HR (95% CI) for dipstick glucosuria was 1.475 (1.166–1.849, P < 0.001). DM subjects with glucosuria (N = 4655) had a higher HR [1.302 (1.044–1.613, P = 0.020)] than DM subjects without glucosuria (N = 20,245), and non-DM subjects with glucosuria (N = 470) had a higher HR [2.511 (1.539–3.833, P < 0.001)] than non-DM subjects without glucosuria (N = 183,690).

Conclusion

Dipstick glucosuria significantly affected mortality in Japanese community-based screening participants.
Literatur
2.
Zurück zum Zitat Iseki K, Asahi K, Moriyama T, et al. Risk factor profiles based on eGFR and dipstick proteinuria: analysis of the participants of the Specific Health Check and Guidance System in Japan 2008. Clin Exp Nephrol. 2012;16:244–9.CrossRefPubMed Iseki K, Asahi K, Moriyama T, et al. Risk factor profiles based on eGFR and dipstick proteinuria: analysis of the participants of the Specific Health Check and Guidance System in Japan 2008. Clin Exp Nephrol. 2012;16:244–9.CrossRefPubMed
4.
Zurück zum Zitat Iseki K, Konta T, Asahi K, et al. Association of dipstick hematuria with all-cause mortality in the general population: results from the Specific Health Check and Guidance Program in Japan. Nephrol Dial Transpl. 2017. https://doi.org/10.1093/ndt/gfx213. (Epub ahead of print).CrossRef Iseki K, Konta T, Asahi K, et al. Association of dipstick hematuria with all-cause mortality in the general population: results from the Specific Health Check and Guidance Program in Japan. Nephrol Dial Transpl. 2017. https://​doi.​org/​10.​1093/​ndt/​gfx213. (Epub ahead of print).CrossRef
5.
Zurück zum Zitat Calado J, Loeffler J, Sakallioglu O, et al. Familial renal glucosuria: SLC5A2 mutation analysis and evidence of salt-wasting. Kidney Int. 2006;59:852–5.CrossRef Calado J, Loeffler J, Sakallioglu O, et al. Familial renal glucosuria: SLC5A2 mutation analysis and evidence of salt-wasting. Kidney Int. 2006;59:852–5.CrossRef
6.
Zurück zum Zitat Haque SK, Ariceta G, Batlle D. Proximal renal tubular acidosis: a not so rare disorder of multiple etiologies. Nephrol Dial Transpl. 2012;27:4273–87.CrossRef Haque SK, Ariceta G, Batlle D. Proximal renal tubular acidosis: a not so rare disorder of multiple etiologies. Nephrol Dial Transpl. 2012;27:4273–87.CrossRef
7.
Zurück zum Zitat Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–28.CrossRefPubMed Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–28.CrossRefPubMed
8.
Zurück zum Zitat Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375(4):323–34.CrossRefPubMed Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375(4):323–34.CrossRefPubMed
9.
Zurück zum Zitat DeFronzo RA, Norton L, Abdul-Ghani M. Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. Nat Rev Nephrol. 2017;13:11–26.CrossRefPubMed DeFronzo RA, Norton L, Abdul-Ghani M. Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. Nat Rev Nephrol. 2017;13:11–26.CrossRefPubMed
10.
Zurück zum Zitat Hung CC, Lin HYH, Lee JJ, et al. Glycosuria and renal outcomes in patients with nondiabetic advanced chronic kidney disease. Sci Rep. 2016;6:39372.CrossRefPubMedPubMedCentral Hung CC, Lin HYH, Lee JJ, et al. Glycosuria and renal outcomes in patients with nondiabetic advanced chronic kidney disease. Sci Rep. 2016;6:39372.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Matsuo S, Imai E, Horio M, et al. Collaborators developing the Japanese equation for estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53(6):982–92.CrossRefPubMed Matsuo S, Imai E, Horio M, et al. Collaborators developing the Japanese equation for estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53(6):982–92.CrossRefPubMed
12.
Zurück zum Zitat American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2011;34(Suppl 1):S62–S69.CrossRefPubMedCentral American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2011;34(Suppl 1):S62–S69.CrossRefPubMedCentral
13.
Zurück zum Zitat Sato Y, Yano Y, Fujimoto S, et al. Glycohemoglobin not as predictive as fasting glucose as a measure of prediabetes in predicting proteinuria. Nephrol Dial Transpl. 2012;27(10):3862–8.CrossRef Sato Y, Yano Y, Fujimoto S, et al. Glycohemoglobin not as predictive as fasting glucose as a measure of prediabetes in predicting proteinuria. Nephrol Dial Transpl. 2012;27(10):3862–8.CrossRef
14.
Zurück zum Zitat Lal RA, Maahs DM. Clinical use of continuous glucose monitoring in pediatrics. Diabetes Technol Ther. 2017;19(S2):S37–S43.CrossRefPubMed Lal RA, Maahs DM. Clinical use of continuous glucose monitoring in pediatrics. Diabetes Technol Ther. 2017;19(S2):S37–S43.CrossRefPubMed
15.
Zurück zum Zitat Kovatchev BP. Metrics for glycaemic control—from HbA1c to continuous glucose monitoring. Nat Rev Endocrinol. 2017;13(7):425–36.CrossRefPubMed Kovatchev BP. Metrics for glycaemic control—from HbA1c to continuous glucose monitoring. Nat Rev Endocrinol. 2017;13(7):425–36.CrossRefPubMed
16.
Zurück zum Zitat Andersson DK, Lundblad E, Svardsudd K. A model for early diagnosis of type 2 diabetes mellitus in primary health care. Diabetes Med. 1993;10:167–73.CrossRef Andersson DK, Lundblad E, Svardsudd K. A model for early diagnosis of type 2 diabetes mellitus in primary health care. Diabetes Med. 1993;10:167–73.CrossRef
17.
Zurück zum Zitat Kondo M, Yamagata K, Hoshi SL, et al. Budget impact analysis of chronic kidney disease mass screening test in Japan. Clin Exp Nephrol. 2014;18(6):885 – 91.CrossRefPubMedPubMedCentral Kondo M, Yamagata K, Hoshi SL, et al. Budget impact analysis of chronic kidney disease mass screening test in Japan. Clin Exp Nephrol. 2014;18(6):885 – 91.CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Nagai M, Murakami Y, Tamakoshi A, et al. Fasting but not casual blood glucose is associated with pancreatic cancer mortality in Japanese: EPOCH-JAPAN. Cancer Causes Control. 2017;28(6):625–33.CrossRefPubMed Nagai M, Murakami Y, Tamakoshi A, et al. Fasting but not casual blood glucose is associated with pancreatic cancer mortality in Japanese: EPOCH-JAPAN. Cancer Causes Control. 2017;28(6):625–33.CrossRefPubMed
19.
Zurück zum Zitat Perkovic V, Agarwal R, Fioretto P, et al. Management of patients with diabetes and CKD: conclusions from a “Kidney Disease: improving Global Outcomes” (KDIGO) Controversies Conference. Kidney Int. 2016;90:1175–83.CrossRefPubMed Perkovic V, Agarwal R, Fioretto P, et al. Management of patients with diabetes and CKD: conclusions from a “Kidney Disease: improving Global Outcomes” (KDIGO) Controversies Conference. Kidney Int. 2016;90:1175–83.CrossRefPubMed
20.
Zurück zum Zitat Wang JY, Yang JH, Xu J, et al. Renal tubular damage may contribute more to acute hyperglycemia induced kidney injury in non-diabetic conscious rats. J Diabetes Complicat. 2015;29:621–8.CrossRefPubMed Wang JY, Yang JH, Xu J, et al. Renal tubular damage may contribute more to acute hyperglycemia induced kidney injury in non-diabetic conscious rats. J Diabetes Complicat. 2015;29:621–8.CrossRefPubMed
21.
Zurück zum Zitat Slyne J, Slattery C, McMorrow T, et al. New developments concerning the proximal tubule in diabetic nephropathy: in vitro models and mechanisms. Nephrol Dial Transpl. 2015;30(Suppl 4):iv60–i67.CrossRef Slyne J, Slattery C, McMorrow T, et al. New developments concerning the proximal tubule in diabetic nephropathy: in vitro models and mechanisms. Nephrol Dial Transpl. 2015;30(Suppl 4):iv60–i67.CrossRef
22.
Zurück zum Zitat Nordquist L, Friederich-Persson M, Fasching A, et al. Activation of hypoxia-inducible factors prevents diabetic nephropathy. J Am Soc Nephrol. 2015;26:328 – 38.CrossRefPubMed Nordquist L, Friederich-Persson M, Fasching A, et al. Activation of hypoxia-inducible factors prevents diabetic nephropathy. J Am Soc Nephrol. 2015;26:328 – 38.CrossRefPubMed
23.
Zurück zum Zitat Tang SC, Yiu WH, Lin M, et al. Diabetic nephropathy and proximal tubular damage. J Ren Nutr. 2015;25:230–3.CrossRefPubMed Tang SC, Yiu WH, Lin M, et al. Diabetic nephropathy and proximal tubular damage. J Ren Nutr. 2015;25:230–3.CrossRefPubMed
24.
Zurück zum Zitat Terami N, Ogawa D, Tachibana H, et al. Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice. PLoS One. 2014;9:e100777.CrossRefPubMedPubMedCentral Terami N, Ogawa D, Tachibana H, et al. Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice. PLoS One. 2014;9:e100777.CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Wanner C. EMPA-REG outcome: the nephrologist’s point of view. Am J Cardiol. 2017;120(suppl):S59-S67.PubMed Wanner C. EMPA-REG outcome: the nephrologist’s point of view. Am J Cardiol. 2017;120(suppl):S59-S67.PubMed
28.
Zurück zum Zitat Selph S, Dana T, Blazina I, et al. Screening for type 2 diabetes mellitus: a systematic review for the US Preventive Services Task Force. Ann Intern Med. 2015;162:765–76.CrossRefPubMed Selph S, Dana T, Blazina I, et al. Screening for type 2 diabetes mellitus: a systematic review for the US Preventive Services Task Force. Ann Intern Med. 2015;162:765–76.CrossRefPubMed
29.
Zurück zum Zitat Zhang L, Long J, Jiang W, et al. Trends in chronic kidney disease in China. N Engl J Med. 2016;375(9):905–6.CrossRefPubMed Zhang L, Long J, Jiang W, et al. Trends in chronic kidney disease in China. N Engl J Med. 2016;375(9):905–6.CrossRefPubMed
30.
Zurück zum Zitat Barzilai N, Crandall JP, Kritchevsky SB, Espeland MA. Metformin as a tool to target aging. Cell Matb. 2016;23:1060–5.CrossRef Barzilai N, Crandall JP, Kritchevsky SB, Espeland MA. Metformin as a tool to target aging. Cell Matb. 2016;23:1060–5.CrossRef
31.
Zurück zum Zitat Griffin SJ, Leaver JK, Irving GJ. Impact of metformin on cardiovascular disease: a meta-analysis of randomized trials among people with type 2 diabetes. Diabetologia. 2017;60:1620–9.CrossRefPubMedPubMedCentral Griffin SJ, Leaver JK, Irving GJ. Impact of metformin on cardiovascular disease: a meta-analysis of randomized trials among people with type 2 diabetes. Diabetologia. 2017;60:1620–9.CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat Kocogullari CU, Kunt AT, Aksoy R, et al. Hemoglobin A1c predicts acute kidney injury after coronary artery bypass surgery in non-diabetic patients. Braz J Cardiovasc Surg. 2017;32(2):83 – 9.PubMedPubMedCentral Kocogullari CU, Kunt AT, Aksoy R, et al. Hemoglobin A1c predicts acute kidney injury after coronary artery bypass surgery in non-diabetic patients. Braz J Cardiovasc Surg. 2017;32(2):83 – 9.PubMedPubMedCentral
33.
Zurück zum Zitat Krolewski AS, Skupien J, Rossing P, et al. Fast renal decline to end-stage renal disease: an unrecognized feature of nephropathy in diabetes. Kidney Int. 2017;91(6):1300–11.CrossRefPubMedPubMedCentral Krolewski AS, Skupien J, Rossing P, et al. Fast renal decline to end-stage renal disease: an unrecognized feature of nephropathy in diabetes. Kidney Int. 2017;91(6):1300–11.CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat Yokoyama H, Kanno S, Takahashi S, et al. Determinants of decline in glomerular filtration rate in nonproteinuric subjects with or without diabetes and hypertension. Clin J Am Soc Nephrol. 2009;4:1432–40.CrossRefPubMedPubMedCentral Yokoyama H, Kanno S, Takahashi S, et al. Determinants of decline in glomerular filtration rate in nonproteinuric subjects with or without diabetes and hypertension. Clin J Am Soc Nephrol. 2009;4:1432–40.CrossRefPubMedPubMedCentral
37.
Zurück zum Zitat Wada T, Haneda M, Furuichi K, et al. Clinical impact of albuminuria and glomerular filtration rate on renal and cardiovascular events, and all-cause mortality in Japanese patients with type 2 diabetes. Clin Exp Nephrol. 2014;18:613–20.CrossRefPubMed Wada T, Haneda M, Furuichi K, et al. Clinical impact of albuminuria and glomerular filtration rate on renal and cardiovascular events, and all-cause mortality in Japanese patients with type 2 diabetes. Clin Exp Nephrol. 2014;18:613–20.CrossRefPubMed
38.
Zurück zum Zitat Yamagata K, Makino H, Iseki K, et al. Effect of behavior modification on outcome in early- to moderate-stage chronic kidney disease: a cluster-randomized trial. PLoS One. 2016;11(3):e0151422.CrossRefPubMedPubMedCentral Yamagata K, Makino H, Iseki K, et al. Effect of behavior modification on outcome in early- to moderate-stage chronic kidney disease: a cluster-randomized trial. PLoS One. 2016;11(3):e0151422.CrossRefPubMedPubMedCentral
39.
Zurück zum Zitat Sekikawa A, Tominaga M, Takahashi K, et al. Prevalence of diabetes and impaired glucose tolerance in Funagata area, Japan. Diabetes Care. 1993;16(4):570–4.CrossRefPubMed Sekikawa A, Tominaga M, Takahashi K, et al. Prevalence of diabetes and impaired glucose tolerance in Funagata area, Japan. Diabetes Care. 1993;16(4):570–4.CrossRefPubMed
40.
Zurück zum Zitat Tominaga M, Eguchi H, Manaka H, et al. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care. 1999;22(6):920–4.CrossRefPubMed Tominaga M, Eguchi H, Manaka H, et al. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care. 1999;22(6):920–4.CrossRefPubMed
41.
Zurück zum Zitat de Jong PE, Curhan GC. Screening, monitoring, and treatment of albuminuria: public health perspectives. J Am Soc Nephrol. 2006;17:2120–6.CrossRefPubMed de Jong PE, Curhan GC. Screening, monitoring, and treatment of albuminuria: public health perspectives. J Am Soc Nephrol. 2006;17:2120–6.CrossRefPubMed
Metadaten
Titel
Glucosuria and all-cause mortality among general screening participants
verfasst von
Kunitoshi Iseki
Tsuneo Konta
Koichi Asahi
Kunihiro Yamagata
Shouichi Fujimoto
Kazuhiko Tsuruya
Ichiei Narita
Masato Kasahara
Yugo Shibagaki
Toshiki Moriyama
Masahide Kondo
Chiho Iseki
Tsuyoshi Watanabe
For the “Design of the Comprehensive Health Care System for Chronic Kidney Disease (CKD) Based on the Individual Risk Assessment by Specific Health Check”
Publikationsdatum
01.08.2018
Verlag
Springer Singapore
Erschienen in
Clinical and Experimental Nephrology / Ausgabe 4/2018
Print ISSN: 1342-1751
Elektronische ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-017-1528-0

Weitere Artikel der Ausgabe 4/2018

Clinical and Experimental Nephrology 4/2018 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.